DNA repair pathways in clinical practice: Lessons from pediatric cancer susceptibility syndromes

Journal of Clinical Oncology

Volumn 24, Issue 23, 2006, Pages 3799-3808

  Kennedy, Richard D ^a   D'Andrea, Alan D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

BREAST CANCER; CANCER CELL; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOMAL INSTABILITY; CLINICAL PRACTICE; DNA REPAIR; DRUG SENSITIVITY; FANCONI ANEMIA; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; ADOLESCENT; CHILD; DISORDERS OF DNA SYNTHESIS AND REPAIR; DNA DAMAGE; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; METABOLISM; MUTATION; NEOPLASM; PREDICTION AND FORECASTING; PRESCHOOL CHILD; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DNA DAMAGE; DNA REPAIR; DNA REPAIR-DEFICIENCY DISORDERS; FANCONI ANEMIA; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MUTATION; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 33747376928     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.4171     Document Type: Review

References (108)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
2. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 396:643-649, 1998
3. Macaluso M, Montanari M, Cinti C, et al: Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol 32:452-457, 2005
4. Bartkova J, Horejsi Z, Koed K, et al: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864-870, 2005
5. Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature 411:366-374, 2001
6. Boudsocq F, Benaim P, Canitrot Y, et al: Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase beta. Mol Pharmacol 67:1485-1492, 2005
7. Zhang X, Miao X, Liang G, et al: Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 65:722-726, 2005
8. Hung RJ, Hall J, Brennan P, et al: Genetic polymorphisms in the base excision repair pathway and cancer risk: A HuGE review. Am J Epidemiol 162:925-942, 2005
9. Gurubhagavatula S, Liu G, Park S, et al: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594-2601, 2004
10. Stoehlmacher J, Ghaderi V, Iobal S, et al: A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21:3075-3079, 2001
11. de Las Penas R, Sanchez-Ronco M, Alberola V, et al: Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17:668-675, 2006
12. Robertson KA, Bullock HA, Xu Y, et al: Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res 61:2220-2225, 2001
13. Trivedi RN, Almeida KH, Fornsaglio JL, et al: The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 65:6394-6400, 2005
14. Albertella MR, Lau A, O'Connor MJ: The overexpression of specialized DNA polymerases in cancer. DNA Repair (Amst) 4:583-593, 2005
15. Aebi S, Kurdi-Haidar B, Gordon R, et al: Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56:3087-3090, 1996
16. Kane MF, Loda M, Gaida GM, et al: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57:808-811, 1997
17. Peltomaki P: Deficient DNA mismatch repair: A common etiologic factor for colon cancer. Hum Mol Genet 10:735-740, 2001
18. Fiumicino S, Martinelli S, Colussi C, et al: Sensitivity to DNA cross-linking chemotherapeutic agents in mismatch repair-defective cells in vitro and in xenografts. Int J Cancer 85:590-596, 2000
19. Papouli E, Cejka P, Jiricny J: Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res 64:3391-3394, 2004
20. Lehmann AR: DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Biochimie 85:1101-1111, 2003
21. Furuta T, Ueda T, Aune G, et al: Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62:4899-4902, 2002
22. Zhou W, Gurubhagavatula S, Liu G, et al: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10:4939-4943, 2004
23. King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646, 2003
24. Liede A, Karlan BY, Narod SA: Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: A review of the literature. J Clin Oncol 22:735-742, 2004
25. Cybulski C, Gorski B, Debniak T, et al: NBS1 is a prostate cancer susceptibility gene. Cancer Res 64:1215-1219, 2004
26. Digweed M, Sperling K: Nijmegen breakage syndrome: Clinical manifestation of defective response to DNA double-strand breaks. DNA Repair (Amst) 3:1207-1217, 2004
27. Kennedy RD, Quinn JE, Johnston PG, et al: BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 360:1007-1014, 2002
28. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819, 2004
29. Ege M, Ma Y, Manfras B, et al: Omenn syndrome due to ARTEMIS mutations. Blood 105:4179-4186, 2005
30. Moshous D, Pannetier C, Chasseval Rd R, et al: Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J Clin Invest 111:381-387, 2003
31. O'Driscoll M, Cerosaletti KM, Girard PM, et al: DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell 8:1175-1185, 2001
32. Riballo E, Critchlow SE, Teo SH, et al: Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr Biol 9:699-702, 1999
33. Rigas B, Borgo S, Elhosseiny A, et al: Decreased expression of DNA-dependent protein kinase, a DNA repair protein, during human colon carcinogenesis. Cancer Res 61:8381-8384, 2001
34. Wilson CR, Davidson SE, Margison GP, et al: Expression of Ku70 correlates with survival in carcinoma of the cervix. Br J Cancer 83:1702-1706, 2000
35. Komuro Y, Watanabe T, Hosoi Y, et al: The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer 95:1199-1205, 2002
36. Omori S, Takiguchi Y, Suda A, et al: Suppression of a DNA double-strand break repair gene, Ku70, increases radio- and chemosensitivity in a human lung carcinoma cell line. DNA Repair (Amst) 1:299-310, 2002
37. Adachi N, Suzuki H, Iiizumi S, et al: Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: Implications for the repair of topoisomerase II-mediated DNA damage. J Biol Chem 278:35897-35902, 2003
38. Bavoux C, Hoffmann JS, Cazaux C: Adaptation to DNA damage and stimulation of genetic instability: The double-edged sword mammalian DNA polymerase kappa. Biochimie 87:637-646, 2005
39. Yang J, Chen Z, Liu Y, et al: Altered DNA polymerase iota expression in breast cancer cells leads to a reduction in DNA replication fidelity and a higher rate of mutagenesis. Cancer Res 64:5597-5607, 2004
40. Nojima K, Hochegger H, Saberi A, et al: Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res 65:11704-11711, 2005
41. Hahn SA, Greenhalf B, Ellis I, et al: BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214-221, 2003
42. Cantor S, Drapkin R, Zhang F, et al: The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci U S A 101:2357-2362, 2004
43. Couch FJ, Johnson MR, Rabe K, et al: Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 65:383-386, 2005
44. van der Heijden MS, Brody JR, Gallmeier E, et al: Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 165:651-657, 2004
45. Condie A, Powles RL, Hudson CD, et al: Analysis of the Fanconi anaemia complementation group A gene in acute myeloid leukaemia. Leuk Lymphoma 43:1849-1853, 2002
46. Tischkowitz MD, Morgan NV, Grimwade D, et al: Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia 18:420-425, 2004
47. Esteller M, Silva JM, Dominguez G, et al: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564-569, 2000
48. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005
49. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917, 2005
50. Lindahl T: Instability and decay of the primary structure of DNA. Nature 362:709-715, 1993
51. Harfe BD, Jinks-Robertson S: DNA mismatch repair and genetic instability. Annu Rev Genet 34:359-399, 2000
52. Fink D, Aebi S, Howell SB: The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4:1-6, 1998
53. Parsons R, Li GM, Longley MJ, et al: Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 75:1227-1236, 1993
54. Tornaletti S, Hanawalt PC: Effect of DNA lesions on transcription elongation. Biochimie 81:139-146, 1999
55. Hanawalt PC: Subpathways of nucleotide excision repair and their regulation. Oncogene 21:8949-8956, 2002
56. Khanna KK, Jackson SP: DNA double-strand breaks: Signaling, repair and the cancer connection. Nat Genet 27:247-254, 2001
57. Zhong Q, Chen CF, Li S, et al: Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 285:747-750, 1999
58. Moynahan ME, Pierce AJ, Jasin M: BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7:263-272, 2001
59. Davies AA, Masson JY, McIlwraith MJ, et al: Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7:273-282, 2001
60. Buscemi G, Savio C, Zannini L, et al: Chk2 activation dependence on Nbs1 after DNA damage. Mol Cell Biol 21:5214-5222, 2001
61. Meek K, Gupta S, Ramsden DA, et al: The DNA-dependent protein kinase: The director at the end. Immunol Rev 200:132-141, 2004
62. Yamashita YM, Okada T, Matsusaka T, et al: RAD18 and RAD54 cooperatively contribute to maintenance of genomic stability in vertebrate cells. Embo J 21:5558-5566, 2002
63. Friedberg EC, Lehmann AR, Fuchs RP: Trading places: How do DNA polymerases switch during translesion DNA synthesis? Mol Cell 18:499-505, 2005
64. Wang J, Kawamura K, Tada Y, et al: DNA polymerase kappa, implicated in spontaneous and DNA damage-induced mutagenesis, is overexpressed in lung cancer. Cancer Res 61:5366-5369, 2001
65. Kennedy RD, D'Andrea AD: The Fanconi anemia/BRCA pathway: New faces in the crowd. Genes Dev 19:2925-2940, 2005
66. Hegde MR, Chong B, Blazo ME, et al: A homozygous mutation in MSH6 causes Turcot syndrome. Clin Cancer Res 11:4689-4693, 2005
67. Masutani C, Kusumoto R, Yamada A, et al: The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. Nature 399:700-704, 1999
68. D'Andrea A: Fanconi anemia. Curr Biol 13:R546, 2003
69. Kanamori M, Kon H, Nobukuni T, et al: Microsatellite instability and the PTEN1 gene mutation in a subset of early onset gliomas carrying germline mutation or promoter methylation of the hMLH1 gene. Oncogene 19:1564-1571, 2000
70. D'Andrea AD, Grompe M: The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3:23-34, 2003
71. Meetei AR, de Winter JP, Medhurst AL, et al: A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 35:165-170, 2003
72. Garcia-Higuera I, Taniguchi T, Ganesan S, et al: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7:249-262, 2001
73. Bridge WL, Vandenberg CJ, Franklin RJ, et al: The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crsslink repair. Nat Genet 37:953-957, 2005
74. Levitus M, Waisfisz Q, Godthelp BC, et al: The DNA Helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 37:934-935, 2005
75. Levran O, Attwooll C, Henry RT, et al: The BRCA1-interacting helicase BRIP1 is deficient in Fanconi Anemia. Nat Genet 39:931-933, 2005
76. Litman R, Peng M, Jin Z, et al: BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 8:255-265, 2005
77. Niedzwiedz W, Mosedale G, Johnson M, et al: The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. Mol Cell 15:607-620, 2004
78. Kutler DI, Singh B, Satagopan J, et al: A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101:1249-1256, 2003
79. Auerbach AD, Allen RG: Leukemia and preleukemia in Fanconi anemia patients: A review of the literature and report of the International Fanconi Anemia Registry. Cancer Genet Cytogenet 51:1-12, 1991
80. Alter BP: Cancer in Fanconi anemia, 1927-2001. Cancer 97:425-440, 2003
81. Offit K, Levran O, Mullaney B, et al: Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 95:1548-1551, 2003
82. Hirsch B, Shimamura A, Moreau L, et al: Association with spontaneous chromosomal instability and solid tumors of childhood. Blood 103:2554-2559, 2004
83. Kutler DI, Auerbach AD, Satagopan J, et al: High incidence of head and neck squamous cell carcinoma in patients with fanconi anemia. Arch Otolaryngol Head Neck Surg 129:106-112, 2003
84. Knudson AG Jr: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68:820-823, 1971
85. Dhillon VS, Shahid M, Husain SA: CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer 3:33, 2004
86. Narayan G, Arias-Pulido H, Nandula SV, et al: Promoter hypermethylation of FANCF: Disruption of Fanconi anemia-BRCA pathway in cervical cancer. Cancer Res 64:2994-2997, 2004
87. Marsit CJ, Liu M, Nelson HH, et al: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: Implications for treatment and survival. Oncogene 23:1000-1004, 2004
88. Koul S, McKiernan JM, Narayan G, et al: Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer 3:16, 2004
89. Taniguchi T, Tischkowitz M, Ameziane N, et al: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9:568-574, 2003
90. Teodoridis JM, Hall J, Marsh S, et al: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65:8961-8967, 2005
91. Narayan G, Arias-Pulido H, Koul S, et al: Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: Its relationship to clinical outcome. Mol Cancer 2:24, 2003
92. Xie Y, de Winter JP, Waisfisz Q, et al: Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells. Br J Haematol 111:1057-1064, 2000
93. Hilton JL, Geisler JP, Rathe JA, et al: Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94:1396-1406, 2002
94. Yuan SS, Lee SY, Chen G, et al: BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 59:3547-3551, 1999
95. Hedenfalk I, Duggan D, Chen Y, et al: Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539-548, 2001
96. Zanier R, Briot D, Dugas du Villard JA, et al: Fanconi anemia C gene product regulates expression of genes involved in differentiation and inflammation. Oncogene 23:5004-5013, 2004
97. Esteller M: Relevance of DNA methylation in the management of cancer. Lancet Oncol 4:351-358, 2003
98. Taron M, Rosell R, Felip E, et al: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13:2443-2449, 2004
99. Cass I, Baldwin RL, Varkey T, et al: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187-2195, 2003
100. Chappuis PO, Goffin J, Wong N, et al: A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 39:608-610, 2002
101. Taniguchi T, Garcia-Higuera I, Andreassen PR, et al: S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 100:2414-2420, 2002
102. van der Heijden MS, Brody JR, Dezentje DA, et al: In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11:7508-7515, 2005
103. Morrison C, Smith GC, Stingl L, et al: Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis. Nat Genet 17:479-482, 1997
104. Calabrese CR, Batey MA, Thomas HD, et al: Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies. Clin Cancer Res 9:2711-2718, 2003
105. Chen J, Silver DP, Walpita D, et al: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 2:317-328, 1998
106. Koberle B, Masters JR, Hartley JA, et al: Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9:273-276, 1999
107. Sugasawa K, Okuda Y, Saijo M, et al: UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin ligase complex. Cell 121:387-400, 2005
108. Hardeland U, Steinacher R, Jiricny J, et al: Modification of the human thymine-DNA glycosylase by ubiquitin-like proteins facilitates enzymatic turnover. Embo J 21:1456-1464, 2002